Salubris(SZ:002294) Guohai Securities·2025-08-21 12:31Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - The company reported a year-on-year increase in revenue and net profit for the first half of 2025, with revenue reaching 2.131 billion yuan (up 4.32% YoY) and net profit at 365 million yuan (up 6.10% YoY) [2][6] - The second quarter of 2025 saw a significant acceleration in profit growth, with revenue of 1.069 billion yuan (up 12.30% YoY) and net profit of 165 million yuan (up 14.55% YoY) [6] - The company is focusing on building a differentiated product matrix in the hypertension field, with ongoing innovation and R&D efforts [6] Financial Performance Summary - For the first half of 2025, the company achieved a gross margin of 75.31%, an increase of 4.55 percentage points YoY, and a net profit margin of 16.14%, up 0.78 percentage points YoY [6] - R&D expenses for the first half of 2025 amounted to 542 million yuan, representing 25.43% of revenue [6] - The company has submitted four drug IND applications in the first half of 2025, with two products receiving clinical trial approvals and two registration certificates [6] Earnings Forecast - Projected revenues for 2025, 2026, and 2027 are 4.628 billion yuan, 5.389 billion yuan, and 6.282 billion yuan, respectively, with corresponding net profits of 982 million yuan, 1.069 billion yuan, and 1.183 billion yuan [8][9] - The report anticipates a continuous increase in earnings per share (EPS) from 0.54 yuan in 2024 to 1.06 yuan in 2027 [8][9] - The price-to-earnings (P/E) ratio is expected to decrease from 57.05x in 2025 to 47.36x in 2027, indicating potential value appreciation [8][9]